Heteroduplex oligonucleotides designed to silence α-synuclein reduced pathological protein accumulation and preserved dopaminergic neurons in two independent Parkinson's disease mouse models. The neuroprotection depended on restored BDNF–TrkB signaling, and BDNF overexpression alone limited α-synuclein aggregation, indicating a bidirectional relationship between the aggregating protein and neurotrophic support. The work advances gene-silencing chemistry as a route to slowing rather than masking neurodegeneration.
Key Points
- Two α-synuclein-silencing oligonucleotides preserved dopaminergic neurons in mice
- Neuroprotection required intact BDNF–TrkB neurotrophic signaling
- BDNF overexpression independently reduced α-synuclein aggregation in vivo
Longevity Analysis
Removing the pathological driver — excess α-synuclein — restored the brain's own repair signaling rather than compensating for its loss, a sequence that mirrors how neural regeneration generally responds to reduced interference. The reciprocal loop between protein aggregation and BDNF also gives clinicians a measurable readout: circulating or central BDNF may track both disease burden and treatment response before motor decline becomes irreversible. For brain aging more broadly, this reinforces protein clearance capacity and neurotrophic tone as linked levers, both of which are influenced by sleep depth, aerobic capacity, and metabolic control long before pharmacology enters the picture.
Original published by Wiley Aging Cell, by Xuenan Wang, Yiru Ding, Lujuan He, Xizhi Kang, Xiwen Geng, Fumika Sakaue, Takanori Yokota, Liang‐wen Zhang, Wei Yao, Ji‐chun Zhang .